Pilar G.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1/2 Evaluation of Relatlimab and Nivolumab in Pediatric and Young Adult Patients with Recurrent or Refractory Classical Hodgkin and Non-Hodgkin Lymphoma
- Evaluation of Odronextamab, Loncastuximab Tesirine, and CAR T-cell Therapy in Pediatric and Adolescent Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase I/II Evaluation of Sodium 2-HYDROXYLINOLEATE, Irinotecan, and Temozolomide in Pediatric Relapsed/Refractory Neuroblastoma and Solid Tumors
Data & Insights
Has run more than one trial at 6 of 36 partner sites.
Specializations
Pediatric Hematologic Malignancies
Focus on childhood blood cancers, including Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, with emphasis on high‑risk and relapsed disease.
- Risk‑adapted chemotherapy protocols
- Minimal residual disease monitoring
- Targeted agents for FLT3‑mutated AML
Research integrates molecular profiling to refine therapeutic stratification.
Pediatric Solid Tumors and Sarcomas
Investigation of solid malignancies such as osteosarcoma, Ewing sarcoma, and high‑grade glioma, addressing both localized and metastatic disease.
- Neoadjuvant and adjuvant multimodal regimens
- Biomarker‑driven targeted therapies
- Precision surgery combined with systemic treatment
Efforts aim to improve survival while reducing treatment‑related toxicity.
Bone Marrow Transplant and Graft‑Versus‑Host Disease
Clinical work on pediatric hematopoietic stem cell transplantation, focusing on prevention and management of acute graft‑versus‑host disease and related complications.
- Optimized conditioning regimens
- Prophylactic immunosuppression strategies
- Biomarker‑guided early intervention
Studies seek to enhance engraftment success and long‑term graft tolerance.
Immunotherapy and Cellular Therapies
Application of novel immune‑based approaches, including CAR T‑cell therapy and bispecific antibodies, for refractory pediatric malignancies.
- Safety and efficacy assessment in acute lymphoblastic leukemia
- Combination with checkpoint inhibition
- Manufacturing and delivery optimization for children
Goal is to expand curative options beyond conventional chemotherapy.
Pediatric Infectious and Metabolic Complications
Study of opportunistic infections such as nontuberculous mycobacterial lung disease and metabolic liver disorders including non‑alcoholic steatohepatitis in immunocompromised children.
- Diagnostic biomarker development
- Therapeutic regimens tailored to pediatric pharmacokinetics
- Integration with oncology supportive care
Research supports comprehensive management of comorbid conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
